BioCryst Pharmaceuticals (BCRX) and Clearside Biomedical (CLSD) announced the entry into a license agreement enabling BioCryst to develop its investigational plasma kallikrein inhibitor, avoralstat, with Clearside’s SCS Microinjector to deliver avoralstat directly to the back of the eye through the suprachoroidal space to treat patients with diabetic macular edema. Under the terms of the agreement, Clearside will receive a $5M upfront license fee from BioCryst. Clearside is eligible to receive up to an additional $30M in clinical and regulatory milestone payments, and up to a total of $47.5M in three post-approval sales-based milestone payments as annual global net sales progress to $2B. BioCryst will pay Clearside tiered mid-single digit royalties on annual global net product sales, at three tiers, including a top tier of greater than $1.5B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BCRX:
- BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®
- BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months
- BioCryst price target lowered to $10 from $11 at Jefferies
- BioCryst price target lowered to $6 from $8 at Barclays
- BioCryst sees FY23 global net ORLADEYO revenue no less than $320M
